GLP-1 Check — India's GLP-1 Information & Self-Assessment Tool

Generic Tirzepatide (Mounjaro) in India

Updated May 2026 · Patent status + alternatives

The short answer

No Indian generic tirzepatide exists yet (as of May 2026). Eli Lilly holds the Indian patent on tirzepatide with expected expiry approximately 2028-2030. The only tirzepatide brand available in India is Mounjaro (₹14,000-27,500/month). Cost-sensitive patients typically switch to semaglutide (a different molecule, well-established, with Indian generics from ₹220/shot). Take the 5-min eligibility check to see what fits.

Not sure if you need tirzepatide specifically?

The 5-minute Indian-guideline check often shows semaglutide is the right fit.

Take the free assessment →

Why is there no Indian generic tirzepatide yet?

Eli Lilly holds the Indian patent on tirzepatide, the active molecule in Mounjaro. Indian generic manufacturers (Sun Pharma, Dr Reddy’s, Zydus, Cipla, Glenmark, Torrent, MSN Labs, Alkem, Mankind) cannot legally produce or sell generic tirzepatide until the patent expires.

The semaglutide patent expired on March 20, 2026 — and within 2 weeks, 10+ Indian generic semaglutide brands launched (Sundae, Noveltreat, Obeda, Semaglyn, Semasize, Semanext, GLIPIQ, Sembolic, Samakind, Semabest, plus innovator co-marketed brands Extensior and Poviztra). Tirzepatide is expected to follow the same pattern, but several years later.

When will Indian generic tirzepatide be available?

Estimated 2028-2030.Eli Lilly’s Indian patent timeline isn’t fully public, but global tirzepatide patent expiry is expected in this range. After expiry, the typical Indian generic launch process takes 6-12 months (DCGI bioequivalence approval, manufacturing scale-up, distribution).

Expected timeline

  • 2026-2027: Mounjaro innovator continues as sole tirzepatide option in India. Eli Lilly may introduce additional dose strengths or partner brands.
  • 2028: Estimated patent expiry window opens. Indian manufacturers begin Phase III bioequivalence trials.
  • 2029-2030: First Indian generic tirzepatide launches expected, following the semaglutide playbook — prices likely 70-90% below innovator.
  • 2030+: Mature Indian generic tirzepatide market, similar to where semaglutide is today.

What to do if you want tirzepatide-class therapy now

Option 1: Pay for Mounjaro (innovator)

₹14,000-27,500/month depending on dose. The only legitimate route to tirzepatide therapy in India until generic launch. Best for patients where the SURMOUNT-grade weight loss (~22% at 15 mg) justifies the cost vs ~15% on Wegovy at ~30-50% lower monthly cost. See Mounjaro India brand page for full pricing and clinical evidence.

Option 2: Use semaglutide instead

Semaglutide (Wegovy for obesity, Ozempic for T2D, plus 10+ Indian generic brands at ₹220-3,500/month) is the well-established alternative. Different molecule but same therapeutic class. ~15% weight loss at 2.4 mg (STEP-1, NEJM 2021) — meaningful for most patients, even if less than tirzepatide’s ~22%. See Semaglutide vs Tirzepatide comparison.

Option 3: Wait for the generic

Only realistic if your clinical situation is non-urgent. For T2D or established obesity comorbidities, waiting 2-4 years for generic tirzepatide is rarely the right call when effective semaglutide options exist today.

Frequently asked questions

Is there a generic Mounjaro (tirzepatide) in India?+
Not yet, as of May 2026. Eli Lilly holds the Indian patent on tirzepatide, with expected expiry in the 2028-2030 timeframe. Indian generic manufacturers (Sun Pharma, Dr Reddy's, Zydus, Cipla, Glenmark, Torrent, MSN Labs) cannot legally produce generic tirzepatide until the patent expires. The semaglutide patent expired in March 2026, which is why a wave of Indian generic semaglutides launched that month — tirzepatide will follow the same pattern, but several years later.
When will generic tirzepatide become available in India?+
Estimated 2028-2030, based on Eli Lilly's Indian patent timeline and the typical Indian regulatory process (Phase III bioequivalence study + DCGI approval). Once the patent expires, expect a similar competitive wave to what happened with semaglutide in March 2026 — multiple Indian manufacturers launching at 70-90% lower prices than the innovator. Until then, the only tirzepatide brand available in India is Eli Lilly's Mounjaro.
What is the cheapest tirzepatide option in India?+
Mounjaro (Eli Lilly's innovator brand) is the only tirzepatide option in India, priced at ₹14,000-27,500/month depending on dose. The 2.5 mg starting dose is at the lower end; the 15 mg target dose for weight management is at the upper end. There is no cheaper tirzepatide alternative — every generic Indian semaglutide brand contains semaglutide (a different molecule), not tirzepatide.
Can I use a semaglutide brand instead of waiting for generic tirzepatide?+
Yes — semaglutide and tirzepatide are both effective GLP-1-class therapies for type 2 diabetes and weight management. Semaglutide has been available globally since 2017, with extensive real-world experience. Indian generic semaglutides cost ₹220-3,500/month (Sundae, Noveltreat, Obeda, Semaglyn, Semabest, Semasize) — dramatically cheaper than Mounjaro. Trade-off: tirzepatide produces greater weight loss (~22% vs ~15% per SURMOUNT-1 vs STEP-1) but at 5-25× higher cost than Indian generic semaglutide.
Why is tirzepatide so expensive in India even though Mounjaro is on the market?+
Mounjaro is the innovator brand, protected by Eli Lilly's Indian patent. Until patent expiry, Eli Lilly is the sole supplier, which keeps prices at innovator levels. India has no exchange-rate or import barriers that would lower the price further; the Mounjaro price reflects global pricing dynamics for novel patented therapies. Once the patent expires (estimated 2028-2030), Indian generic competition will drop prices substantially — similar to how semaglutide prices fell 70-90% in March-April 2026.
Are there any tirzepatide clinical trials happening in India?+
Eli Lilly conducts global tirzepatide trials with India-inclusive enrollment (the SURMOUNT and SURPASS programmes had Indian study sites). These are innovator trials, not Indian generic trials. Indian generic manufacturers cannot run bioequivalence trials before patent expiry — they will start that process closer to the patent end-date. Outcomes trials specifically for the Indian population (SURMOUNT-CN for Chinese patients is the closest analogue) may emerge but are not yet publicly announced.
Is it ethical or legal to import tirzepatide from countries with cheaper generics?+
There are currently no countries with legal tirzepatide generics — every market with tirzepatide on sale has the Eli Lilly innovator brand. Even if a generic existed elsewhere, India's drug import rules and the Schedule H prescription requirement make personal importation impractical. The safe, legal path for cost-sensitive patients today is the Indian generic semaglutide market (different molecule, well-established).

Related guides

Mounjaro India — price, dose, indication →Semaglutide vs Tirzepatide comparison →Mounjaro vs Wegovy in India →Ozempic alternatives in India →Mounjaro price breakdown India →All Indian semaglutide brands →

See whether semaglutide or tirzepatide fits you

5-minute Indian-guideline eligibility check. Maps your BMI, comorbidities, and goals to the right molecule + dose.

Take the free assessment →

Patent timelines are based on publicly available information and may shift as Eli Lilly’s Indian intellectual property posture evolves. All GLP-1 therapies (tirzepatide, semaglutide) are Schedule H drugs in India requiring a doctor’s prescription. GLP-1 Check is informational and not a substitute for clinical judgment.